JP2002503667A - 新規な二量体化剤、その製造および使用 - Google Patents

新規な二量体化剤、その製造および使用

Info

Publication number
JP2002503667A
JP2002503667A JP2000531451A JP2000531451A JP2002503667A JP 2002503667 A JP2002503667 A JP 2002503667A JP 2000531451 A JP2000531451 A JP 2000531451A JP 2000531451 A JP2000531451 A JP 2000531451A JP 2002503667 A JP2002503667 A JP 2002503667A
Authority
JP
Japan
Prior art keywords
domain
cells
rapalog
fkbp
frb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000531451A
Other languages
English (en)
Japanese (ja)
Inventor
エル シュレイバー,ストゥアート
アール クラブトゥリー,ジェラルド
ディー リバールズ,ステファン
Original Assignee
プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ filed Critical プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ
Publication of JP2002503667A publication Critical patent/JP2002503667A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000531451A 1998-02-13 1999-02-12 新規な二量体化剤、その製造および使用 Withdrawn JP2002503667A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7458498P 1998-02-13 1998-02-13
US60/074,584 1998-02-13
PCT/US1999/003095 WO1999041258A1 (fr) 1998-02-13 1999-02-12 Agents de dimerisation, production et utilisation

Publications (1)

Publication Number Publication Date
JP2002503667A true JP2002503667A (ja) 2002-02-05

Family

ID=22120362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000531451A Withdrawn JP2002503667A (ja) 1998-02-13 1999-02-12 新規な二量体化剤、その製造および使用

Country Status (5)

Country Link
EP (1) EP1053241A1 (fr)
JP (1) JP2002503667A (fr)
AU (1) AU766513B2 (fr)
CA (1) CA2319492A1 (fr)
WO (1) WO1999041258A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511822A (ja) * 2012-03-13 2015-04-23 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスおよび化学二量体を用いる選択細胞の標的化
JP2016531567A (ja) * 2013-07-29 2016-10-13 ブルーバード バイオ, インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
JP2017502690A (ja) * 2013-12-20 2017-01-26 ノバルティス アーゲー 調節可能キメラ抗原受容体
JP2020513036A (ja) * 2017-04-05 2020-04-30 レボリューション メディシンズ インコーポレイテッドRevolution Medicines,Inc. 協同的結合に関与する化合物及びその使用
US11644460B2 (en) 2010-12-28 2023-05-09 Revolution Medicines, Inc. Identifying new therapeutic agents
US11987590B2 (en) 2015-01-09 2024-05-21 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924483D0 (en) * 1999-10-15 1999-12-15 Plant Bioscience Ltd Modified resistance genes
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
KR20130040844A (ko) 2010-03-29 2013-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 약학적으로 유발된 전이유전자 제거 시스템
US20140031418A1 (en) 2011-04-20 2014-01-30 The Trustees Of The University Of Pennsylvania Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
US10634668B2 (en) 2012-09-13 2020-04-28 Takara Bio Usa, Inc. Modifiable chemical inducers of proximity and methods of using the same
WO2014145252A2 (fr) 2013-03-15 2014-09-18 Milone Michael C Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive
WO2015012924A2 (fr) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Cassettes d'expression préférentielle pour tissus modifiées par un codon, vecteurs les contenant, et utilisation
WO2014200659A1 (fr) 2013-06-11 2014-12-18 Clontech Laboratories, Inc. Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
MX2018009405A (es) * 2016-02-04 2018-11-09 Univ Johns Hopkins Sintesis y composicion de bibliotecas de rapafucina.
EP3452103A1 (fr) 2016-04-15 2019-03-13 The Trustees Of The University Of Pennsylvania Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
BR112019017697A2 (pt) 2017-02-28 2020-04-07 Janssen Biotech Inc vacinas contra influenza baseadas em vetores de vírus adenoassociado (aav)
ES2971872T3 (es) 2017-02-28 2024-06-10 Univ Pennsylvania Vector de clado F de virus adenoasociado (AAV) y usos para el mismo
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
MX2020003945A (es) 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
CA3079568A1 (fr) 2017-10-18 2019-04-25 Regenxbio Inc. Agents therapeutiques a base d'anticorps entierement humains a modification post-traductionnelle
EP3723787A4 (fr) 2017-12-14 2021-09-01 Bluebird Bio, Inc. Récepteurs de l'interleukine darique
AU2020253462A1 (en) 2019-04-03 2021-10-28 Regenxbio Inc. Gene therapy for eye pathologies
WO2020219868A1 (fr) 2019-04-24 2020-10-29 Regenxbio Inc. Agents thérapeutiques à base d'anticorps entièrement humains à modification post-traductionnelle
MX2021013417A (es) 2019-05-04 2021-12-10 Inhibrx Inc Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
WO2021041373A1 (fr) 2019-08-26 2021-03-04 Regenxbio Inc. Traitement de la rétinopathie diabétique avec un fab anti-vegf à modification post-traductionnelle complètement humain
EP4041292A1 (fr) 2019-10-07 2022-08-17 RegenxBio Inc. Composition pharmaceutique de vecteur de virus adéno-associé et méthodes
WO2022060916A1 (fr) 2020-09-15 2022-03-24 Regenxbio Inc. Anticorps vectorisés pour thérapie antivirale
WO2022060915A1 (fr) 2020-09-15 2022-03-24 Regenxbio Inc. Lanadelumab vectorisé et administration de celui-ci
KR20230083287A (ko) 2020-10-07 2023-06-09 리젠엑스바이오 인크. Cln2 질환의 안구 징후에 대한 유전자 요법
WO2022094157A1 (fr) 2020-10-28 2022-05-05 Regenxbio Inc. Anticorps vectorisés anti-cgrp et anti-récepteur de cgrp et leur administration
MX2023004806A (es) 2020-10-28 2023-05-10 Regenxbio Inc Anticuerpos anti-tnf-a vectorizados para indicaciones oculares.
MX2023004843A (es) 2020-10-29 2023-05-10 Regenxbio Inc Antagonistas de tnf-alfa con vectorizacion para indicaciones oculares.
US20230390418A1 (en) 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
AR124216A1 (es) 2020-12-01 2023-03-01 Univ Pennsylvania Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
BR112023021971A2 (pt) 2021-04-23 2024-02-20 Univ Pennsylvania Composições com motivos de direcionamento específicos do cérebro e composições contendo os mesmos
TW202325845A (zh) 2021-10-02 2023-07-01 賓州大學委員會 新穎aav衣殼及含其之組成物
AU2023211652A1 (en) 2022-01-25 2024-08-08 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2023201308A1 (fr) 2022-04-14 2023-10-19 Regenxbio Inc. Thérapie génique pour le traitement d'une maladie oculaire
WO2023205610A2 (fr) 2022-04-18 2023-10-26 Regenxbio Inc. Capsides aav hybrides
WO2023215807A1 (fr) 2022-05-03 2023-11-09 Regenxbio Inc. INHIBITEURS VECTORISÉS ANTI-TNF-α POUR INDICATIONS OCULAIRES
TW202400803A (zh) 2022-05-03 2024-01-01 美商銳進科斯生物股份有限公司 載體化抗補體抗體與補體劑及其投與
WO2024073669A1 (fr) 2022-09-30 2024-04-04 Regenxbio Inc. Traitement de maladies oculaires avec des vecteurs viraux recombinés codant un fab anti-vegf
WO2024130067A2 (fr) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Vecteurs mutants aav recombinants avec motifs de ciblage spécifiques des muscles cardiaque et squelettique et compositions les contenant
WO2024130070A2 (fr) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Capsides aav recombinantes avec motifs de ciblage spécifiques du muscle cardiaque et squelettique et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) * 1993-02-02 1993-03-17 Sandoz Ltd Compounds
AU731826B2 (en) * 1996-02-28 2001-04-05 Ariad Pharmaceuticals, Inc. Synthetic Multimerizing Agents

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644460B2 (en) 2010-12-28 2023-05-09 Revolution Medicines, Inc. Identifying new therapeutic agents
JP2015511822A (ja) * 2012-03-13 2015-04-23 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスおよび化学二量体を用いる選択細胞の標的化
US10457731B2 (en) 2013-07-29 2019-10-29 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
US10196444B2 (en) 2013-07-29 2019-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
JP2019146598A (ja) * 2013-07-29 2019-09-05 ブルーバード バイオ, インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
US10428142B2 (en) 2013-07-29 2019-10-01 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
JP2020178690A (ja) * 2013-07-29 2020-11-05 ブルーバード バイオ, インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
JP2016531567A (ja) * 2013-07-29 2016-10-13 ブルーバード バイオ, インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
JP2017502690A (ja) * 2013-12-20 2017-01-26 ノバルティス アーゲー 調節可能キメラ抗原受容体
JP2021000103A (ja) * 2013-12-20 2021-01-07 ノバルティス アーゲー 調節可能キメラ抗原受容体
JP7225174B2 (ja) 2013-12-20 2023-02-20 ノバルティス アーゲー 調節可能キメラ抗原受容体
US11987590B2 (en) 2015-01-09 2024-05-21 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
JP2020513036A (ja) * 2017-04-05 2020-04-30 レボリューション メディシンズ インコーポレイテッドRevolution Medicines,Inc. 協同的結合に関与する化合物及びその使用

Also Published As

Publication number Publication date
CA2319492A1 (fr) 1999-08-19
WO1999041258A1 (fr) 1999-08-19
AU766513B2 (en) 2003-10-16
EP1053241A1 (fr) 2000-11-22
AU2676099A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
JP2002503667A (ja) 新規な二量体化剤、その製造および使用
US6984635B1 (en) Dimerizing agents, their production and use
US7196192B2 (en) 28-epirapalogs
US7067526B1 (en) 28-epirapalogs
AU755784B2 (en) Regulation of biological events using multimeric chimeric proteins
US6187757B1 (en) Regulation of biological events using novel compounds
US6506379B1 (en) Intramuscular delivery of recombinant AAV
US6153383A (en) Synthetic transcriptional modulators and uses thereof
KR19990022651A (ko) 생물학적 사건에 대한 라파마이신 기재 조절방법
US7109317B1 (en) FK506-based regulation of biological events
AU714904C (en) Rapamcycin-based regulation of biological events
US20030206891A1 (en) Rapamycin-based biological regulation
AU1603900A (en) Fk506-based regulation of biological events
JP2002535959A (ja) 条件保持ドメインを含む材料および方法
JP2002535958A (ja) 条件集合ドメインに関する材料および方法
EP0833894B1 (fr) Regulation d'evenements biologiques fondee sur la rapamycine

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060509